ABBV-744

N/A

Report date: 2022/08/19 16:45:31
NME

Base Information

Drug NameABBV-744
Drug Alias NameABBV-744
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain-containing protein 4 inhibitorsBromodomain-containing protein 3 inhibitorsBromodomain-containing protein 2 inhibitors
TargetsBromodomain-containing protein 3Bromodomain-containing protein 2Bromodomain-containing protein 4
Therapy Area/IndicationsPrimary MyelofibrosisLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesSweden +[15] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesN/A
Active IndicationsPrimary Myelofibrosis
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A